TY  - JOUR
AU  - Radujkovic, Aleksandar
AU  - Dietrich, Sascha
AU  - Andrulis, Mindaugas
AU  - Benner, Axel
AU  - Longerich, Thomas
AU  - Pellagatti, Andrea
AU  - Nanda, Kriti
AU  - Giese, Thomas
AU  - Germing, Ulrich
AU  - Baldus, Stefan
AU  - Boultwood, Jacqueline
AU  - Ho, Anthony D
AU  - Dreger, Peter
AU  - Luft, Thomas
TI  - Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
JO  - International journal of cancer
VL  - 139
IS  - 6
SN  - 0020-7136
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2017-05455
SP  - 1402 - 1413
PY  - 2016
AB  - We tested the hypothesis that proliferative activity of hematopoietic stem cells has impact on survival in newly diagnosed patients with myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (AML). RNA expression profiles of CD34(+) cells were analyzed in 125 MDS patients and compared to healthy controls. Prognostic impact on overall survival (OS) of mRNA proliferation signatures established for solid tumor cells was analyzed retrospectively. For validation on the protein level, immunofluorescence and immunohistochemistry analyses in bone marrow (BM) biopsies were performed, and an independent cohort of 223 MDS and secondary AML patients was investigated. Lower proliferative activity correlated with the expression of cyclin-dependent kinase inhibitor 1C (CDKN1C) and with shorter OS (p < 0.001). In multivariable analysis, higher CDKN1C expression was associated with worse OS (p = 0.02). On the BM level, a total of 84 (38
KW  - Antigens, CD34 (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - CDKN1C protein, human (NLM Chemicals)
KW  - Cyclin-Dependent Kinase Inhibitor p57 (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:27170453
DO  - DOI:10.1002/ijc.30181
UR  - https://inrepo02.dkfz.de/record/130376
ER  -